CK Life Sciences Int’l., (Holdings) Inc. announced that Executive Director, Vice President and Chief Executive Officer Mr. Lance Richard Lee Yuen will step down on 8 May 2026 due to personal and family considerations that require relocation to Canada. He will remain a director of the group’s Canadian subsidiaries to oversee local operations. The board recorded its appreciation for Mr. Yuen’s contributions and confirmed there are no disagreements or issues requiring shareholder attention under Listing Rule 13.51(2).

Effective the same date, Executive Director Mr. Yu Ying Choi, Alan Abel is re-designated from Deputy Chairman to Deputy Chairman and Chief Executive Officer. Aged 70, Mr. Yu has been on the executive committee since February 2021 and previously held the CEO post between September 2020 and September 2024, as well as the Chief Operating Officer role from June 2002 to September 2020. He also serves as a director of Dogwood Therapeutics, Inc. in the United States.

Mr. Yu holds personal interests in 2.25 million company shares and is not related to any other directors, senior management, or substantial shareholders. Subject to shareholder approval at the next annual general meeting, his director’s fee as Executive Director, Deputy Chairman and CEO is set at HK$100,000 per annum. The remuneration of executive directors is benchmarked against company performance, profitability and prevailing market conditions.

As of the announcement date, the board comprises six executive directors—including Chairman Mr. Li Tzar Kuoi, Victor—and five non-executive directors, four of whom are independent. No additional matters regarding these leadership changes require disclosure under Listing Rule 13.51(2).